Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients

NACompletedINTERVENTIONAL
Enrollment

353

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

May 16, 2023

Study Completion Date

May 16, 2023

Conditions
NPC
Interventions
OTHER

Epigallocatechin Gallate (EGCG)

EGCG 600 mg per day will be provided to the test group.Four capsules will be taken daily (2# bid) by the test individuals.

DIETARY_SUPPLEMENT

Placebo

Placebo qd (2# bid) for 3 years

Trial Locations (1)

350

Taiwan Cooperative Oncology Group, National Health Research Institutes, Zhunan

All Listed Sponsors
collaborator

Mackay Memorial Hospital

OTHER

collaborator

Taichung Veterans General Hospital

OTHER

collaborator

National Cheng-Kung University Hospital

OTHER

collaborator

Chang Gung Memorial Hospital

OTHER

collaborator

China Medical University Hospital

OTHER

collaborator

National Taiwan University Hospital

OTHER

lead

National Health Research Institutes, Taiwan

OTHER

NCT01744587 - Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients | Biotech Hunter | Biotech Hunter